Chief Development Officer
Trevi Therapeutics
13
0
11
N/A
0
10
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (13)
Showing 10 of 13 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Jason Wu
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Shared therapeutic areas:
Paolo Bonato, PhD
Spaulding Rehabilitation Hospital
Shared therapeutic areas:
Herbert B Slade, MD
Healthpoint
Shared therapeutic areas:
loic MONDOLONI
Assistance Publique Hopitaux De Marseille
Shared therapeutic areas:
Pablo Tebas, MD
University of Pennsylvania
Shared therapeutic areas:
Xinghua Gao
First Hospital of China Medical University
Shared therapeutic areas:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
Zhaohui Zhu, MD
Peking Union Medical College Hospital
Shared therapeutic areas:
James C Eisenach, MD
Wake Forest University Health Sciences
Shared therapeutic areas:
Suman Sheraz, PhD*
Riphah International University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (13)
Showing 13 of 13 trials
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
NAL ER IPF Respiratory Function and Safety Study
A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants
Cough Reduction in IPF With Nalbuphine ER
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
PRISM Study-Pruritus Relief Through Itch Scratch Modulation
Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
All 13 trials loaded